Research areas

  • Mechanisms of resistance to monoclonal antibody therapy in B-cell malignancies
  • Identification of novel therapy targets through genome-wide knockout screens using CRISPR/Cas9 technology
  • Repurposing of approved drugs for personalized therapy in hematological cancers (chronic lymphocytic leukemia, acute myeloid leukemia)
  • Improvement of CAR-T cell therapy for chronic lymphocytic leukemia
  • Mechanisms of resistance to Venetoclax and prediction of alternative therapies in acute myeloid leukemia

Main objectives

Content of research


Michal Šmída
Michal Šmída
Research Group Leader Junior
Personal Profile